Allergan and Gedeon Richter Plc today announced they will present data on the investigational drug cariprazine in patients with schizophrenia and acute mania in bipolar I disorder during the 28th European College of Neuropsychopharmacology (ECNP) annual congress in Amsterdam, 29 August–1 September 2015.
Data presented include the first detailed results of cariprazine for the potential treatment of schizophrenia patients with predominant negative symptoms.
Richter Poster
Monday 31 August, 12:15–1:45 pm CEST
• Cariprazine as Monotherapy for the Treatment of Schizophrenia Patients with Predominant Negative Symptoms: A Double-Blind, Active Controlled Trial (abstract #P.3.d.053), authored by Debelle, M., Nemeth, G., Szalai, E., Szatmari, B., Harsanyi, J., Barabassy, A., Laszlovszky, I.
Allergan and Richter Posters
Monday 31 August 12:15–1:45 pm CEST
• Long-Term Cariprazine Treatment for the Prevention of Relapse in Patients With Schizophrenia: A Double-Blind, Placebo-Controlled Trial (abstract #P.3.d.057), authored by Durgam, S., Earley, W., Li, R., Li, D., Lu, K., Laszlovszky, I., Fleischhacker, W.W., Lieberman, J.A.
• Categorical Improvement Across Mania Symptoms: Pooled Analyses of Cariprazine Phase II/III Trials (abstract #P.2.d.014), authored by Durgam, S., Laszlovszky, I., Lu, K., Ruth, A., Debelle, M., Zukin, S.
Tuesday 1 September 12:15–1:45 pm CEST
• Cariprazine Reduces Agitation and Hostility Associated With Schizophrenia (abstract #P.3.d.073), authored by Citrome, L., Lu, K., Ferguson, P., Laszlovszky, I., Earley, W., Durgam, S.
